Basit öğe kaydını göster

Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience

dc.contributor.authorBektas, Fatih
dc.contributor.authorSadri, Sevil
dc.contributor.authorKeskin, Dilek
dc.contributor.authorÖZGÜR YURTTAŞ, Nurgül
dc.contributor.authorELVERDİ, Tuğrul
dc.contributor.authorSALİHOĞLU, Ayşe
dc.contributor.authorAR, Muhlis Cem
dc.contributor.authorÖNGÖREN, Şeniz
dc.contributor.authorBAŞLAR, Zafer
dc.contributor.authorAydin, Yildiz
dc.contributor.authorSoysal, Teoman
dc.contributor.authorEŞKAZAN, Ahmet Emre
dc.contributor.authorOzmen, Deniz
dc.contributor.authorÖZTAŞ, Mert
dc.contributor.authorBayraktar, Esref Alperen
dc.date.accessioned2021-12-10T11:30:33Z
dc.date.available2021-12-10T11:30:33Z
dc.date.issued2021
dc.identifier.citationEŞKAZAN A. E. , Ozmen D., ÖZTAŞ M., Bektas F., Bayraktar E. A. , Sadri S., Keskin D., ÖZGÜR YURTTAŞ N., ELVERDİ T., SALİHOĞLU A., et al., "Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.8, ss.549-557, 2021
dc.identifier.issn2152-2650
dc.identifier.otherav_827d301b-d720-4a53-9f2e-3fb978ef80bf
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172029
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.04.005
dc.description.abstractWe retrospectively compared the efficacy and safety of frontline imatinib between elderly patients (>= 60 years old) and younger patients ( <60 years old) with chronic myeloid leukemia (CML). Response rates were similar in both groups. Event-free survival was comparable, and overall survival-when non-CML-related deaths were censored-was also similar. Age at diagnosis and the Charlson comorbidity index were significantly associated with overall survival. In the era of tyrosine kinase inhibitors, survival of patients with CML is determined more by comorbidities than by the disease itself.
dc.language.isoeng
dc.subjectHematology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleEfficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume21
dc.identifier.issue8
dc.identifier.startpage549
dc.identifier.endpage557
dc.contributor.firstauthorID2717055


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster